Science 37 Appoints SVP, Erica Prowisor, to Bolster Patient Recruitment Velocity, Diversity

New role supports the Company’s objective to lead the industry with faster, more inclusive clinical research

RESEARCH TRIANGLE PARK, N.C., April 25, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies.

Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company’s direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Operations, in charge of global operations for the company’s Accelerated Enrollment Solutions business.

“As a Metasite, we access patients that can’t be accessed by traditional brick and mortar sites, and we have proven to enroll patients significantly faster on almost every single trial,” said Darcy Forman, Chief Delivery Officer at Science 37. “With Erica’s prolific experience in patient recruitment, we are excited to further accelerate our recruitment velocity and extend our leadership position, while also gaining efficiencies that can lower our cost per acquisition.”

"The Science 37 Metasite™ offers a unique opportunity to transform clinical trials by providing expansive access,” said Erica Prowisor. “I look forward to being able to help drive better patient outcomes by finding the most representative patient populations, regardless of location."

Science 37 boasts myriad channels for recruiting patients including its own network of more than 600 thousand patients, approximately 35 thousand community providers that reach approximately 35 million patient lives, in addition to partnerships with third-party patient communities, pharmacies, labs, associations and digital media outlets. The company uses an omnichannel approach to find patients and a high-efficiency enrollment process that includes an online screening process, a technology-enabled contact center, and eConsent to ensure that no patient is left behind.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.

Media Inquiries

Grazia Mohren

Science 37

PR@science37.com

Investor Relations

Steve Halper

LifeSci Advisors

Investors@science37.com

Science 37 Adds New Head of Quality, Irena Lambridis

New role supports the Company’s objective to be the DCT industry’s “undisputed leader” in quality

RESEARCH TRIANGLE PARK, N.C., April 18, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally.

Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA Biotech). With her extensive knowledge of good clinical practices (GCP), GXP, and computer systems validation, she and her team will provide full quality and compliance oversight for the company.

"We are thrilled to welcome Irena to our senior leadership team," said David Coman, CEO of Science 37. "Her expertise in protocol complexity, sponsor complexity including CROs, organizational complexity and scale, globalization, and all disciplines of quality and compliance will ensure that Science 37 is positioned as the undisputed leader of quality in our industry. We look forward to her making an immediate impact."

"I am excited to join Science 37's experienced, patient-focused team and help bring new therapies to market faster," said Lambridis. "As virtual clinical trials become increasingly important, I am eager to use my expertise to ensure the highest quality of data and compliance at all times."

In her new role, Irena will play a vital part in Science 37's mission to accelerate clinical research by enabling universal trial access for patients through virtual clinical trials. Her appointment reflects the company's ongoing commitment to excellence and will be key to driving greater efficiency, speed, and scale as Science 37 expands its global reach.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.

Media Inquiries

Grazia Mohren

Science 37

PR@science37.com

Investor Relations

Steve Halper

LifeSci Advisors

Investors@science37.com

Science 37 Names Industry Veteran Michael Shipton as Chief Commercial Officer

RESEARCH TRIANGLE PARK. September 12, 2022—Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced that Michael Shipton has been appointed Chief Commercial Officer to lead business development, strategic solutions, sales operations, and strategic pricing, effective today.

With more than 25 years of commercial leadership experience in clinical research and technology, Michael served most recently as Senior Vice President, Customer Solutions & Strategy at Syneos Health (“Syneos”). During his tenure with Syneos, Michael led a team that successfully drove strategic relationships that generated more than $1 billion in enterprise sales. He previously served as Senior Vice President, Market Development and Customer Engagement, which included accountability for global deal strategy, enterprise sales operations, global sales training, inside sales, customer engagement, and business insights. Michael also previously held executive and leadership roles at IQVIA and Nortel.

“Michael has a proven track record of designing and delivering customized business solutions to solve complex clinical research needs at a very large scale,” said David Coman, Chief Executive Officer, Science 37. “As the materiality, size, and complexity of the studies we’re being asked to support, continue to increase, Michael’s enterprise-level solution orientation is the perfect fit and will help us to achieve our ambitious growth plans.”

 “After working on clinical trials for so long, it is clear that the industry is ripe for the kind of disruption that Science 37 can deliver to patients, providers, sponsors, and CROs,” said Shipton. “I’m excited to actively participate in helping reduce patient burden, enable providers to deliver clinical research as a care option, enable CROs with the tools to deploy elements of decentralization for their trials and sponsors to get drugs to market faster.”

“I would like to thank Steve Geffon for generating transformational growth for Science 37 over the past two and a half years,” said Mr. Coman. “Steve built an outstanding commercial management team and mature commercial business processes. He will transition to a role as a strategic advisor to the CEO.”

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 21x faster enrollment, 28% better retention, and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation, and data harmonization. For more information, visit https://www.science37.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37, its sales pipeline and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on Nasdaq, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business and changes in its capital structure, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, and (vi) the potential adverse effects of the ongoing global COVID-19 pandemic. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 22, 2022 and in our other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.

MEDIA INQUIRIES:

Drew Bustos

Science 37

PR@science37.com

INVESTOR RELATIONS:

Caroline Paul

Science 37 // Gilmartin

Investors@science37.com

Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth

RESEARCH TRIANGLE PARK, N.C., March 31, 2022 — Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it is fortifying its oncology and hematology research acumen by adding Shaalan Beg, M.D., M.S.C.S. to its Global Management Team.

Dr. Beg comes to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, Texas where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer and held the position of Director Gastrointestinal (GI) Medical Oncology and Associate Professor of Hematology and Medical Oncology. Nationally, Dr. Beg is a member of the American Society of Clinical Oncology (ASCO) and the ECOG-ACRIN Clinical Research Group and has held various committee positions in these organizations. He is a graduate of ASCO’s Leadership Development Program and has been a member of the Pancreatic Cancer Task Force of the National Cancer Institute (NCI) GI Cancer Steering Committee.

His medical and research training, combined with in-depth experience as a clinical trial investigator and background of clinical trial design and execution, adds comprehensive capacity and operational prowess to Science 37’s Operating Systems and its ability to configure more agile and decentralized oncology studies.

“We are pleased to have Dr. Beg join Science 37,” said Jonathan Cotliar, M.D., Chief Medical Officer of Science 37. “He brings a wealth of clinical trial expertise and has been at the forefront of understanding the benefit of agile and decentralized clinical trial design for oncology studies from his leadership roles at UT Southwestern Medical Center, as well as NCI’s National Clinical Trial Network. His experience builds on our mission of enabling universal access for patients and providers, anywhere.” 

“Science 37’s leadership and drive toward more agile and decentralized clinical trials is long overdue in cancer research,” said Shaalan Beg, M.D., M.S.C.S., Vice President, Oncology at Science 37. “It’s a very transformative moment for the industry and I’m looking forward to helping remove the barriers patients face when participating in research. This will further enable access and help ensure the most appropriate clinical trial is available to the patients who need them most.”

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Agile Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full-stack, end-to-end technology platform, and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES

Drew Bustos

Science 37

Phone: (984) 377-3737

Email: pr@science37.com

INVESTOR RELATIONS:

Caroline Paul

Gilmartin

Investors@science37.com

Emily Rollins Appointed to Science 37® Board of Directors

With this important addition to its Board of Directors, Science 37 further advances its mission to accelerate clinical trials by enabling universal access to patients and providers.

Science 37, the Operating System for today’s more agile clinical trials, announced the appointment of Emily Rollins to the Company’s Board of Directors. Ms. Rollins will serve as the chairperson for the Science 37’s Audit Committee.

Ms. Rollins, a retired Deloitte audit and assurance partner, brings more than 30 years of expertise as she has guided hundreds of clients—from pre-revenue to $10B+ international public companies—through corporate governance, audit and reporting processes. She chairs multiple board committees from various industries. As a deeply trusted advisor to executive teams, Ms. Rollins is an ideal addition to the Science 37 Board of Directors. 

“We are thrilled to welcome Emily to the Science 37 Board,” said David Coman, Chief Executive Officer of Science 37. “She is a renowned accounting expert with years of experience advising companies in various stages of growth from a variety of industries. She also shares our passion for increasing access to clinical research for patients and providers—helping make research more representative and accelerating the development of potentially life-saving treatments. We are truly fortunate to have the opportunity to benefit from her perspectives as a board member.”

“Science 37’s aim to make clinical research more accessible for more people is a shared passion and being a part of the Board of Directors at this pivotal moment is an exciting opportunity for me.” said Emily Rollins, director and Audit Committee chairperson, Science 37 Board of Directors. “I look forward to working with the executive team as they look to leverage their operating system to disrupt the traditional clinical trial model and make research more efficient to help speed treatments to market for the people who need them.”

About Science 37: 
Science 37, Inc.’s missions it to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators and connected devices. Configurable to enable any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:
Drew Bustos
Science 37
Phone: (984) 377-3737
Email: pr@science37.com

INVESTOR RELATIONS:
Caroline Paul
Gilmartin Group
investors@science37.com

Science 37® Appoints Christine Pellizzari as Chief Legal Officer

With this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers


 
Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced that Christine Pellizzari has joined the senior executive team as Chief Legal Officer. In this role, Pellizzari will use her nearly 30 years of legal expertise to manage the legal and quality functions to help advance Science 37’s mission to enable universal access to clinical research for patients and providers, anywhere.


 
Ms. Pellizzari joins Science 37 from Insmed Incorporated, a biotechnology company focused on advancing treatments for serious and rare diseases, where she served for more than eight years, most recently as Chief Legal Officer. Additionally, she serves on the boards of two development stage biotechnology companies, Celsion Corporation (Nasdaq: CLSN) and Tempest Therapeutics (Nasdaq: TPST). Ms. Pellizzari has built and led the legal departments at public companies in the biopharmaceutical and technology space for more than two decades, making her an ideal fit for the Science 37 leadership team.


 
“We are extraordinarily pleased to add Christine to our Science 37 leadership team,” said David Coman, Chief Executive Officer of Science 37. “Not only does she have the legal experience to guide our continued global expansion, but her deep industry and regulatory expertise strengthens our ability to increase access to clinical trials for patients and providers—helping to accelerate the development of treatments that impact patient lives.”


 
“Joining the executive team at Science 37 is a wonderful opportunity to be part of a dynamic, fast-growing market. Decentralized clinical trials are disrupting clinical research and I am honored to provide Science 37 with the legal support to navigate these exciting times,” said Christine Pellizzari, Chief Legal Officer of Science 37. “I look forward to putting my expertise to work traversing this fast-moving and highly regulated sector, and helping to advance Science 37’s mission to accelerate clinical research by enabling universal access to patients and providers.”


 
About Science 37: 
Science 37 accelerates clinical research by enabling universal access to patients and providers, anywhere. The Science 37 Operating System™—underpinned by an end-to-end technology platform and supported by specialized networks to enable trial orchestration—enables up to15x faster trial enrollment, 28x greater patient retention and 3x more diversity. Science 37 and it’s Operating System can be configured to conduct the full clinical trial, act as a virtual site (known as Metasite™) or deploy its technology in combination with any of its specialized networks to enable flexibility across nearly any study design. Founded in 2014 as a pioneer in decentralized clinical trials, Science 37 has conducted more fully-decentralized, interventional clinical trials than any other provider and has the most complete Operating System. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook.


 
MEDIA INQUIRIES:
Drew Bustos
VP, Marketing & Communications, Science 37
Margie.Kooman@science37.com
Science 37
984. 377.3737
 
INVESTOR RELATIONS:
Caroline Paul
Gilmartin Group
investors@science37.com

John Hubbard, Ph.D., Joins Science 37® Board of Directors

Science 37, the industry leader in decentralized clinical trials, today announced the appointment of industry veteran John Hubbard, Ph.D., FCP to its Board of Directors.

Dr. Hubbard brings more than three decades of experience across multiple senior executive roles with the industry’s foremost organizations. Most recently, he was President and Chief Executive Officer at Bioclinica, a leading medical imaging and technology-enabled clinical services provider. During Dr. Hubbard’s tenure, the company completed four strategic acquisitions that strengthened and broadened its capabilities to support clinical development. Bioclinica doubled in size and expanded its customer base to include the top 100 pharmaceutical companies and the top 10 contract research organizations. Prior to Bioclinica, Dr. Hubbard was Senior Vice President and Worldwide Head of Development Operations at Pfizer. Earlier in his career, Dr. Hubbard helped fuel exponential growth for ICON plc as its Group President of the Global Clinical Research Service Division.

“We’re pleased to have John join the Board of Directors,” said Robert C. Faulkner, chairman of the Science 37 Board of Directors. “With more than 30 years of leadership experience in the biopharmaceutical and pharma services industries, John brings tremendous insight and strategic direction to enable Science 37’s growth. His experience in building organizations and capitalizing on market potential is especially valuable as we look to make virtual trials the new reality for sponsors and patients.”

“John joins the Science 37 Board of Directors at a perfect time,” said David Coman, Chief Executive Officer of Science 37. “As we continue to accelerate our growth, John’s experience with companies on a similar trajectory will bring extraordinary value and guidance. We look forward to leveraging his expertise going forward.”

Dr. Hubbard commented, “I am delighted to be joining the Science 37 Board of Directors during this critical time in biopharmaceutical development. Now, more than ever we need to apply innovation, cutting-edge technology and telemedicine principles to accelerate biopharmaceutical product development. Finding a safe and effective vaccine to treat COVID-19 has been a catalyst for our industry to re-think the drug development paradigm. The philosophy, operations, and technology of Science 37 embrace this new approach and I look forward to working with Rob, David, and our Board of Directors as we grow Science 37 and help to provide patients better access to new cutting-edge therapies.”

Dr. Hubbard is currently a Board Member of Advarra and Agile Therapeutics (NASDAQ: AGRX), Chairman of Signant Health, and was a founding member of the Board of Directors of TransCelerate Biopharma Inc., a leading biopharma industry consortium. Dr. Hubbard holds a Bachelor’s of Science from the University of Santa Clara, a Ph.D. from the University of Tennessee, and was a NIH Postdoctoral Fellow at the University of Texas Health Sciences Center at San Antonio.

About Science 37
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, we provide access to patients who can never be reached by traditional site-based models. We have proven to enroll faster, retain patients at a higher rate, and reach a more representative population. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive network of telemedicine investigators and home-health nurses, who are supported by the industry’s most comprehensive, fully integrated, decentralized clinical trial platform. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook. 

MEDIA INQUIRIES

Drew Bustos

Science 37

Phone: (984) 377-3737

Email: pr@science37.com

INVESTOR RELATIONS:

Caroline Paul

Gilmartin

Investors@science37.com

Science 37® Appoints Mike Zaranek as Chief Financial Officer

Executive role applies financial rigor to ensure profitable growth as the company continues to scale.

Science 37, the industry leader in virtual clinical trials, announced today that Mike Zaranek has joined the company as its chief financial officer (CFO). He will oversee all aspects of finance, accounting, and strategic pricing as the company prepares for its next stage of growth.

Zaranek joins Science 37 from IQVIA’s Contract Sales and Medical Solutions, where he served as vice president of finance for the global business unit, which had 2019 revenues of more than $800 million. In this role, Zaranek set the financial strategy, drove growth, and developed financial structures to enhance customer value. He was also responsible for financial planning and analysis, segment reporting, and led financial due diligence on prospective acquisition targets. Previously, Zaranek spent almost two decades in corporate development roles, with a focus on mergers and acquisitions as well as capital market transactions. He holds a bachelor’s degree in accounting from The Pennsylvania State University and earned his master’s degree in business administration from Duke University. 

“Mike has built a successful track record in his career by maximizing customer value and delivering transformational growth with strong financial strategies,” said David Coman, CEO of Science 37. “I’m confident that his business acumen, leadership, and experience will help Science 37 extend its market-leading position.”

“I’m excited to join Science 37,” said Zaranek. “I believe it’s the right company in the right space at the right time. I look forward to helping the team build upon its strong foundation and enabling the company to accelerate its growth globally.”

Science 37 has conducted more fully decentralized, interventional clinical trials than any other company, and is powered by the industry’s first and only comprehensive, integrated technology platform that is purpose-built to execute virtual trials. 

About Science 37

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, we provide access to patients who can never be reached by traditional site-based models. We have proven to enroll faster, retain patients at a higher rate, and reach a more representative population. Science 37 has conducted more decentralized, interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses, who are supported by the industry’s most comprehensive, fully integrated, decentralized clinical trial platform. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook

Contact:

Drew Bustos
Science 37

Phone: (984) 377-3737

Email: pr@science37.com

Science 37® Appoints Darcy Forman as Chief Delivery Officer

Science 37, the industry leader in decentralized clinical trials, recently announced that Jonathan Commons and Darcy Forman have joined the company as vice president of patient engagement and vice president of clinical operations, respectively. The additions help Science 37 extend its market-leading capabilities in clinical trial services and delivery of enhanced experiences for both patients and sponsors.  

“Adding Jonathan and Darcy to our executive team enables us to extend our leadership in the decentralized trials market,” said David Coman, CEO of Science 37. “Jonathan’s deep experience in patient engagement coupled with Darcy’s breadth of experience in clinical operations, set us on an exhilarating path that will allow us to create additional value for sponsors and further enhance the patient experience.”

As vice president of patient engagement, Commons joins Science 37 from Optum, a global health services company that is part of UnitedHealth Group, where he was managing director of the Innovation Solutions Group and responsible for developing data-driven customer insights for health engagement. Prior to Optum, Commons honed his expertise at AbleTo Inc., a leading provider of virtual behavioral healthcare, where he was vice president of consumer engagement. He has also held a variety of digital strategy and marketing leadership positions at GlaxoSmithKline and IQVIA. As vice president of patient engagement at Science 37, Commons will oversee all aspects of patient recruitment and engagement, including the entire patient journey.

“Joining Science 37 is a rare opportunity to be at the forefront of patient-centered research, and I look forward to building on the momentum Science 37 has created in transforming the patient experience and optimizing patient recruitment,” Commons said. 

Forman, vice president of clinical operations, joins Science 37 from Firma Clinical Research, a contract research organization (CRO), where she was most recently vice president of corporate development and had previously led global clinical operations.  Prior to Firma, Forman held leadership positions in clinical operations at Clinipace Worldwide, a CRO specializing in supporting growth-oriented and mid-tier pharmaceutical and medical device companies. As vice president of clinical operations at Science 37, Forman will manage all aspects of the clinical trial life cycle, from pre-contract study planning to complete study execution.

“Science 37 has a clear mission, purpose-built technology, and a disruptive approach to clinical research.  I am thrilled to have the opportunity to further enhance the sponsor experience and extend efficiencies in our clinical trial execution,” Forman said.

Science 37 has conducted more fully decentralized, interventional clinical trials than any other organization. The Science 37 model has achieved enrollment timelines that are up to 27 times faster than traditional sites with 90% higher retention rates on the same trial. Research at Science 37 is powered by the industry’s first and only comprehensive, purpose-built platform to fully operationalize a virtual or decentralized trial. 

About Science 37

Science 37 accelerates the availability of life-changing medicines by putting patients first.  Transforming the patient experience, Science 37 extends clinical trial research beyond traditional offices and hospitals and into the comfort and convenience of home. This expansive reach removes barriers to participation so that everyone can benefit from breakthrough research—anytime, anywhere. Recognized as the industry leader, our unrivaled expertise, unparalleled recruitment and retention capabilities, high-touch patient services, and comprehensive platform inspire confidence that Science 37 is uniquely qualified to execute decentralized clinical research with the highest quality, robustness, and regard for patient safety and data integrity. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook.

Contacts

Drew Bustos

Vice President, Marketing

Science 37
Phone: (984) 377-3737
Email: pr@science37.com

Science 37® Appoints Steven Geffon as Chief Commercial Officer

Science 37, the industry leader in decentralized clinical trials, announced today that Steven Geffon has joined the company as its chief commercial officer. He will lead commercial operations and strategic partnerships. 

Geffon joins Science 37 from Medrio, a leading SaaS data capture platform, where he was responsible for sales and marketing as chief commercial officer. Prior to Medrio, Geffon spent nearly 15 years leading a period of explosive growth and profitability at ERT, a global data and technology company that helps minimize risk in clinical trials, where he was most recently group vice president, North America. 

“With a career deeply embedded in the clinical space, I’m excited about the wealth of knowledge and experience that Steven brings to Science 37,” said David Coman, CEO of Science 37. “His commercial expertise and strategic mindset will help extend Science 37 as the clear leader in the decentralized trial market and create unparalleled value for our clients.” 

“Science 37 is delivering game-changing technology and a disruptive approach that are transforming the patient experience and powering a new era of clinical research,” said Geffon. “I couldn’t be more excited to have the opportunity to lead commercial operations and strategic partnerships to help our clients retain and engage patients through our innovative digital technology and home health solutions.” 

Science 37 conducts fully decentralized clinical trials or acts as an additional site to supplement an existing site network. The Science 37 model has achieved enrollment timelines that are up to 27 times faster than traditional sites with 90% higher retention rates on the same trial. It also has been able to recruit six times the number of patients, with first patient in (FPI) within seven weeks of the final protocol. 

About Science 37 Enabled by digital technologies and home health expertise, Science 37 helps accelerate new drug time to market. We transform the patient experience by pushing research beyond traditional offices and hospitals and into the comfort and convenience of home. Our expansive reach removes barriers to participation so that everyone can benefit from breakthrough research—anytime, anywhere. Recognized as the industry leader, our unrivaled expertise, comprehensive platform, and high-touch patient services inspire confidence that Science 37 is uniquely qualified to execute virtual clinical research with the highest quality, robustness, and regard for patient safety and data integrity. The Science 37 model is flexible and scalable, meeting biopharma companies at any point along the virtual clinical research journey. Learn more at Science 37, and follow Science 37 on Twitter, LinkedIn, and Facebook. 

MEDIA INQUIRIES

Drew Bustos

Science 37

Phone: (984) 377-3737

Email: pr@science37.com